Paul Yaswen of the Environmental Genomics & Systems Biology Division was part of a team of researchers from Berkeley Lab, UCSF, and the Buck Institute who co-authored an October 24 Nature Medicine publication on their research that showed the potential of PIM1 kinase inhibition for treatment of patients with triple-negative breast cancer (TNBC). TNBC, which lacks the expression of the estrogen, progesterone, and HER2 receptors, represents the breast cancer subtype with the poorest outcome. No targeted therapy is available against this subtype due to lack of validated molecular targets.